Haddad Jihad A, Annabi Firas O Abbas, Abbasi Hiba, AlSamen Muneer A Abu, Ammari Fawaz L, Haddad Fares H, Haddad Suhair E, Jaradat Mustafa, Khassawneh Adi, Khatib Nidal, Magableh Arabieh, Al-Mousa Eyas
Bader Medical Complex, Suleiman Al-Hadidi St. 19, Amman, Jordan.
Islamic Hospital, Amman, Jordan.
Diabetes Ther. 2025 May;16(5):899-913. doi: 10.1007/s13300-025-01718-7. Epub 2025 Mar 19.
This study investigated the prevalence and clinical management of atherosclerotic cardiovascular disease (ASCVD) and ASCVD risk in patients with type 2 diabetes (T2D) in Jordan.
PACT-MEA (NCT05317845) was a non-interventional, cross-sectional, observational study of adults with T2D recruited in seven countries across the Middle East and Africa. In Jordan, assessments were conducted at ten sites, three in primary care and seven in secondary care settings.
The Jordan cohort included 576 individuals (27.8% primary care, 72.2% secondary care settings), similarly represented by male and female patients, with a mean age of 59.7 ± 11.7 years and a median duration of diabetes of 10.0 years. The prevalence of established ASCVD (eASCVD) was 26.2% overall (95% CI: 22.8-30.0) and 21.9% and 27.9% in primary care and secondary care settings, respectively (95% CI: 16.1-28.9, 23.8-32.4), higher than that observed in the regional PACT-MEA analysis. By the European Society of Cardiology 2021 criteria, 66.0% of patients were classified as high risk and 33.3% as very high risk (which included eASCVD). Use of renin-angiotensin system inhibitors, statins, and cardioprotective antidiabetic medication was higher in secondary care settings. None of the participants achieved all guideline recommendations with respect to risk factor control, body mass index, exercise, and pharmacotherapy.
More than one-quarter of patients with T2D in Jordan had ASCVD, and nearly all were at high/very high ASCVD risk. These findings suggest a need for multifactorial approaches to risk reduction in this population within Jordan in both primary and secondary care settings.
URL: https://www.
gov ; Unique identifier: NCT05317845.
本研究调查了约旦2型糖尿病（T2D）患者中动脉粥样硬化性心血管疾病（ASCVD）的患病率及临床管理情况以及ASCVD风险。
PACT-MEA（NCT05317845）是一项针对中东和非洲七个国家招募的成年T2D患者的非干预性横断面观察性研究。在约旦，评估在十个地点进行，三个在初级保健机构，七个在二级保健机构。
约旦队列包括576名个体（27.8%来自初级保健机构，72.2%来自二级保健机构），男女患者比例相似，平均年龄为59.7±11.7岁，糖尿病病程中位数为10.0年。确诊ASCVD（eASCVD）的总体患病率为26.2%（95%CI：22.8-30.0），在初级保健机构和二级保健机构中分别为21.9%和27.9%（95%CI：16.1-28.9，23.8-32.4），高于区域PACT-MEA分析中观察到的患病率。根据欧洲心脏病学会2021年标准，66.0%的患者被归类为高危，33.3%为极高危（其中包括eASCVD）。二级保健机构中肾素-血管紧张素系统抑制剂、他汀类药物和心脏保护抗糖尿病药物的使用更高。没有参与者在危险因素控制、体重指数、运动和药物治疗方面达到所有指南建议。
约旦超过四分之一的T2D患者患有ASCVD，几乎所有患者都处于ASCVD高/极高风险。这些发现表明，约旦在初级和二级保健机构中都需要采取多因素方法来降低该人群的风险。
网址：https://www.
gov；唯一标识符：NCT05317845。
